Comparison of Adverse Event (AE) Management Costs of Chimeric Antigen Receptor T-Cell (CAR T) Therapies in 4L+ Relapsed And/Or Refractory Multiple Myeloma (RRMM)

anitocabtagene autoleucel (CART-ddBCMA) - Gilead, Kite Pharma

Carvykti (ciltacabtagene autoleucel) - J&J

Abecma (idecabtagene vicleucel) - BMS

Rahul Banerjee, MD, FACP

Sep 11, 2026